Leerink Partnrs Has Negative View of aTyr Pharma Q3 Earnings

Key Points

• Leerink Partners has reduced its Q3 2025 earnings per share estimate for aTyr Pharma to ($0.17), significantly down from the previous estimate of ($0.05).
• Multiple analysts have downgraded their ratings for aTyr Pharma, with Wall Street Zen changing from "hold" to "sell" and HC Wainwright shifting from "buy" to "neutral".
• aTyr Pharma shares have seen a 5.1% drop, with the stock currently trading around $1.03, well below its 52-week high of $7.29.

aTyr Pharma, Inc. (NASDAQ:ATYR - Free Report) - Leerink Partnrs lowered their Q3 2025 earnings per share estimates for aTyr Pharma in a research report issued on Monday, September 15th. Leerink Partnrs analyst F. Khurshid now forecasts that the company will post earnings per share of ($0.17) for the quarter, down from their prior estimate of ($0.05). Leerink Partnrs has a "Hold" rating on the stock. The consensus estimate for aTyr Pharma's current full-year earnings is ($0.91) per share. Leerink Partnrs also issued estimates for aTyr Pharma's Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.68) EPS, Q1 2026 earnings at ($0.08) EPS, Q2 2026 earnings at ($0.05) EPS, Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at ($0.05) EPS and FY2026 earnings at ($0.24) EPS.

Other equities research analysts have also recently issued research reports about the company. Wells Fargo & Company reissued an "equal weight" rating on shares of aTyr Pharma in a research note on Monday. Wall Street Zen cut aTyr Pharma from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th. HC Wainwright cut aTyr Pharma from a "buy" rating to a "neutral" rating in a research report on Monday. Jefferies Financial Group lifted their target price on aTyr Pharma from $9.00 to $17.00 and gave the company a "buy" rating in a research report on Friday, August 22nd. Finally, Cantor Fitzgerald cut aTyr Pharma from an "overweight" rating to a "neutral" rating in a research report on Monday. One investment analyst has rated the stock with a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat.com, aTyr Pharma has an average rating of "Hold" and a consensus price target of $23.25.

aTyr Pharma Trading Down 5.1%

Shares of aTyr Pharma stock opened at $1.03 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.63 and a current ratio of 5.63. aTyr Pharma has a 52 week low of $0.97 and a 52 week high of $7.29. The stock has a 50 day moving average price of $5.11 and a two-hundred day moving average price of $4.32. The stock has a market capitalization of $100.44 million, a PE ratio of -1.28 and a beta of 1.01.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.22) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.04).

Institutional Trading of aTyr Pharma

Several hedge funds have recently made changes to their positions in the company. Oxford Asset Management LLP bought a new stake in shares of aTyr Pharma in the second quarter valued at $70,000. Octagon Capital Advisors LP raised its stake in shares of aTyr Pharma by 7.5% in the second quarter. Octagon Capital Advisors LP now owns 3,820,000 shares of the company's stock valued at $19,367,000 after buying an additional 268,000 shares during the period. BNP Paribas Financial Markets bought a new stake in shares of aTyr Pharma in the second quarter valued at $99,000. California State Teachers Retirement System bought a new stake in shares of aTyr Pharma in the second quarter valued at $28,000. Finally, Raymond James Financial Inc. raised its stake in shares of aTyr Pharma by 79.3% in the second quarter. Raymond James Financial Inc. now owns 24,839 shares of the company's stock valued at $126,000 after buying an additional 10,989 shares during the period. 61.72% of the stock is currently owned by institutional investors.

aTyr Pharma Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.